Text Size
550 studies found for:    Open Studies | "Esophageal Diseases"

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Recruiting Esophageal Cancer Risk Registry
Conditions: Esophageal Cancer;   Gastroesophageal Reflux Disease;   Esophageal Diseases;   Hiatal Hernia;   Esophageal Achalasia
Interventions: Procedure: Survey of client health, personal habits, family history;   Procedure: Blood specimen for non-DNA and DNA parts;   Procedure: Biopsy of esophageal/stomach tissue, lymph nodes, tumor;   Procedure: Biopsies from routine clinical surveillance endoscopies
2 Recruiting Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma;
Conditions: Esophageal Neoplasm;   Esophageal Cancer TNM Staging Primary Tumor (T) T2;   Esophageal Cancer TNM Staging Primary Tumor (T) T3;   Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0;   Esophageal Cancer TNM Staging Distal Metastasis (M) M0
Intervention: Radiation: Prophylactic postoperative radiation therapy
3 Unknown † Evaluation of Topical Mitomycin C as Adjuvant Drug to Esophageal Dilation in Children
Conditions: Esophageal Stricture;   Caustic Esophageal Stricture;   Peptic Esophageal Stricture;   Post-Surgical Esophageal Stricture
Intervention: Drug: Mitomycin C
4 Recruiting Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Stage IB Esophageal Cancer;   Stage IIA Esophageal Cancer;   Stage IIB Esophageal Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIB Esophageal Cancer
Interventions: Radiation: radiation therapy;   Drug: paclitaxel;   Drug: carboplatin;   Biological: trastuzumab;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment
5 Recruiting Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Drug: cyclodextrin-based polymer-camptothecin CRLX101;   Other: Laboratory biomarker analysis;   Other: Pharmacological studies
6 Recruiting Neoadjuvant Chemotherapy vs. Chemoradiation for Resectable Esophageal Cancer
Conditions: Esophageal Cancer;   Adenocarcinoma, Esophageal;   Squamous Cell Carcinoma, Esophageal;   Carcinoma, Gastroesophageal Junction
Interventions: Drug: carboplatin and paclitaxel;   Other: Carboplatin paclitaxel plus concurrent radiotherapy
7 Recruiting Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Primary Hepatocellular Carcinoma;   Chondrosarcoma;   Clear Cell Sarcoma of the Kidney;   Conjunctival Kaposi Sarcoma;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Hormone-resistant Prostate Cancer;   Limited Stage Small Cell Lung Cancer;   Localized Resectable Adult Primary Liver Cancer;   Male Breast Cancer;   Mast Cell Sarcoma;   Ovarian Sarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Cancer;   Recurrent Breast Cancer;   Recurrent Colon Cancer;   Recurrent Esophageal Cancer;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Gastric Cancer;   Recurrent Kaposi Sarcoma;   Recurrent Melanoma;   Recurrent Non-small Cell Lung Cancer;   Recurrent Osteosarcoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Prostate Cancer;   Recurrent Rectal Cancer;   Recurrent Renal Cell Cancer;   Recurrent Small Cell Lung Cancer;   Recurrent Uterine Sarcoma;   Small Intestine Leiomyosarcoma;   Stage I Colon Cancer;   Stage I Rectal Cancer;   Stage I Uterine Sarcoma;   Stage IA Breast Cancer;   Stage IA Gastric Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Breast Cancer;   Stage IB Gastric Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Ovarian Epithelial Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Breast Cancer;   Stage II Uterine Sarcoma;   Stage IIA Colon Cancer;   Stage IIA Gastric Cancer;   Stage IIA Non-small Cell Lung Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIA Rectal Cancer;   Stage IIB Colon Cancer;   Stage IIB Esophageal Cancer;   Stage IIB Gastric Cancer;   Stage IIB Melanoma;   Stage IIB Non-small Cell Lung Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIB Rectal Cancer;   Stage IIC Colon Cancer;   Stage IIC Melanoma;   Stage IIC Ovarian Epithelial Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage IIC Rectal Cancer;   Stage III Uterine Sarcoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Esophageal Cancer;   Stage IIIA Gastric Cancer;   Stage IIIA Melanoma;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Rectal Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Esophageal Cancer;   Stage IIIB Gastric Cancer;   Stage IIIB Melanoma;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Rectal Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Rectal Cancer;   Stage IV Bladder Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer;   Stage IV Melanoma;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Uterine Sarcoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: sirolimus;   Other: laboratory biomarker analysis;   Biological: DEC-205-NY-ESO-1 fusion protein vaccine
8 Recruiting Fully Covered or Partially Covered Stents in Malignant Esophageal Strictures
Conditions: Esophageal Cancer;   Esophageal Stenosis
Interventions: Device: Partially covered SEMS;   Device: Fully covered SEMS
9 Recruiting Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer
Conditions: Esophageal Cancer;   Neoplasms, Esophageal
Interventions: Drug: Everolimus;   Drug: Paclitaxel;   Drug: carboplatin;   Drug: cetuximab
10 Unknown † Chemoradiation and Panitumumab for Esophageal Cancer
Conditions: Squamous Cell Carcinoma;   Adenocarcinoma;   Esophageal Cancer;   Gastro-esophageal Junction Cancer
Interventions: Drug: carboplatin;   Drug: Paclitaxel;   Drug: Panitumumab;   Radiation: 3-D conformal radiation
11 Unknown † A Trial of Esophageal and Gastric Stenting for Leak or Perforation
Conditions: Esophageal or Gastric Perforations;   Esophageal or Gastric Leaks
Intervention: Device: Boston Scientific Ultraflex or Wallstent stents
12 Unknown † Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer
Conditions: Esophageal Cancer;   Malignant Neoplasm of Cardio-esophageal Junction of Stomach
Interventions: Drug: Azacitidine;   Drug: Oxaliplatin;   Drug: Epirubicin;   Drug: Capecitabine
13 Recruiting Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinoma of the Gastroesophageal Junction;   Diffuse Adenocarcinoma of the Stomach;   Intestinal Adenocarcinoma of the Stomach;   Mixed Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage III Esophageal Cancer;   Stage III Gastric Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Drug: pralatrexate;   Drug: oxaliplatin;   Other: pharmacogenomic studies;   Genetic: RNA analysis;   Genetic: polymorphism analysis;   Genetic: polymerase chain reaction;   Genetic: microarray analysis;   Procedure: esophagogastroduodenoscopy;   Procedure: biopsy;   Other: laboratory biomarker analysis
14 Not yet recruiting trūFreeze® Spray Cryotherapy Patient Registry
Conditions: Barrett Esophagus;   Esophageal Dysplasia;   Esophageal Neoplasm;   Esophageal Stenosis;   Bronchial Neoplasm;   Stenosis of Bronchus or Trachea;   Central Airway Cancer
Intervention:
15 Recruiting Self-expandable Esophageal Stent Versus Balloon Tamponade in Refractory Esophageal Variceal Bleeding.
Conditions: Esophageal Varices;   Bleeding;   Cirrhosis
Interventions: Device: Stent;   Device: Tamponade
16 Recruiting Open or Keyhole Surgery Through the Chest for Newborn Babies: Effect on Blood Gases
Conditions: Esophageal Atresia With Tracheo-esophageal Fistula;   Congenital Diaphragmatic Hernia
Interventions: Procedure: Hypercapnia during thoracoscopy;   Procedure: Open surgery
17 Recruiting Observational Field Study of Acute Esophageal Food Bolus Impaction by Mean Esophageal Manometry and 24h-pH-monitoring
Condition: Esophageal Motility Disorders
Intervention:
18 Recruiting Robot-assisted Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy
Conditions: Esophageal Carcinoma;   Esophageal Cancer
Intervention: Procedure: Esophagectomy
19 Recruiting Quality of Life With Esophageal Stent Trial
Conditions: Esophageal Cancer;   Gastro-esophageal Junction Cancer
Interventions: Behavioral: Home visits;   Behavioral: standard
20 Recruiting Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IV Breast Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Drug: Akt inhibitor MK2206;   Biological: trastuzumab;   Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years